Is Mind Medicine a Good Psychedelic Stock to Buy?

: MNMD | Mind Medicine (MindMed) Inc. News, Ratings, and Charts

MNMD – Even as COVID-19 related restrictions ease, mental health issues are on the rise. Consequently, Mind Medicine (MNMD) is attracting investors’ attention due to its drug development pipeline of innovative treatments that are based on psychedelic substances. But, given that the company’s drugs are still in their developmental stage, is it wise to bet on the stock now? Let’s find out.

Psychedelic medicine biotech company Mind Medicine (MindMed) Inc. (MNMD) made its debut on  Nasdaq Capital Market on April 27, 2021 while retaining its listing on the Neo Exchange Inc. under the symbol MMED. The company didn’t have a great market debut as its shares fell 29% on the first day of trading on the Nasdaq. And the stock has lost 25.6% over the past month to close Friday’s trading session at $3.40.

While the demand for treatments based on psychedelic substances is growing because mental health issues are on the rise despite the easing of restrictions related to the COVID-19 pandemic, MNMD’s psychedelic inspired medicines are still in their developmental stage. Also, its net and comprehensive loss for fiscal first quarter ended March 31, 2021 came in at $14 million.

MNMD still has a long way to go to complete the development of its products, so its near-term prospects look bleak. As the company’s co-founder and CEO JR Rahn told Yahoo Finance, “These are still very early innings for us.”

Click here to checkout our Healthcare Sector Report for 2021

Here’s what I think could shape MNMD’s performance in the near term:

Psychedelic Drugs Yet to be Widely Accepted

According to Data Bridge Market Research, the psychedelic drugs market is expected to reach $6,859.95 million by 2027, growing at a 16.3% CAGR. This assumes that the rising prevalence of mental depression and anxiety and the availability of off-label drugs are expected to drive an increasing demand for  psychedelic drugs. However, the market faces some challenges, such as uncertainty surrounding  FDA approval, the early stage in the lifecycle of the psychedelics industry, and a stigma associated with the use of psychedelic drugs, among others. As a result, MNMD may continue  struggling for some time.

Most of MNMD’s Products Still in Developmental Stage

MNMD is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, such as Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. Its LSD experiential therapy, named Project Lucy, is in Phase 2A development, while its 18-MC substance use disorders project is in its Phase 1 development stage. Its LSD Microdosing Adult ADHD is also in Phase 1 development. So, it will likely take the company a significant period to generate revenues from the deployment of  these drugs.

Selling Shares to Fund Growth Activities

MNMD announced on March 9, 2021 that it had closed its offering of  6 million units to raise  gross proceeds of CAD$19.5 million ($16.15 million). Following the offering’s closing, its cash in hand has increased to CAD$205.2 million ($162.0 million).

MNMD is expected to use proceeds from the offering for general working capital and for further investment in Project Lucy, the Microdose LSD Program and Project Albert, which is now integrated with MNMD’s most recent technology acquisition, HealthMode, to build a comprehensive mental health platform to deploy psychedelics medicines.

POWR Ratings Reflect Bleak Prospects

MNMD has an overall D rating, which equates to Sell in our POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree. 

Our proprietary rating system also evaluates each stock based on eight different categories. Among  these categories, MNMD has a D grade for Quality, which is in sync with its negative ROE and ROTC.

The stock has a D grade for Momentum, which is consistent with its 25.6% loss over the past month. It has a D grade for Stability also. 

Beyond what we’ve stated above, we’ve also given MNMD grades for Growth, Value and Sentiment. Get all the MNMD ratings here. MNMD is ranked #268 out of 491 stocks in the Biotech industry.

Better than MNMD: Click here to access 27 top-rated stocks in the same industry.

Bottom Line

MNMD is an emerging player in the psychedelic drug space, but it still has a long way to go. Its EPS is expected to remain negative in its fiscal years 2021 and 2022 because its drugs are still in their early development stage. So, we think it’s wise to avoid the stock now.  

Click here to checkout our Healthcare Sector Report for 2021

Want More Great Investing Ideas?

9 “Must Own” Growth Stocks for 2021

Top 10 Value Stocks

5 Ways to Beat the S&P 500

3 Signs of a NEW Stock Market Bubble


MNMD shares were trading at $3.14 per share on Tuesday morning, down $0.26 (-7.65%). Year-to-date, MNMD has gained 2.95%, versus a 12.78% rise in the benchmark S&P 500 index during the same period.


About the Author: Manisha Chatterjee


Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MNMDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

2nd Half of 2021 Stock Market Outlook

The stock market (SPY) has continued on a bullish path to start 2021. Yet it is not quite the same glorious bull run we enjoyed from the lows of last year. This market has become more volatile and with less upside potential. However, there is still plenty of money to be made if you look in the right places. That is the very nature of the new presentation I put together. So read on for more info…

:  |  News, Ratings, and Charts

Better Meme Stock: Wendy's or Palantir Technologies?

2021 has been the year of the meme stock. Meme stocks have risen higher and faster than many of the traditional big name high flyers this year. These stocks are being pushed higher by traders on social media. Wendy's Company (WEN) and Palantir Technologies (PLTR) are two stocks that have recently generated a lot of attention, but which is a better buy? Read more to find out.

:  |  News, Ratings, and Charts

Is the Stock Market “Melting Up”?

The last few weeks the S&P 500 (SPY) has been beset with wild sector rotation. That is still at play. However, another trend may also be emerging that deserves some conversation. That is the notion of a market “melt up”. What is that? And what does it mean for our trading strategy? I will answer that and more in this week’s commentary. Read on below to find out more…

:  |  News, Ratings, and Charts

4 ETFs to Buy if Inflation is Transitory

Recently, we've seen the biggest inflation reading since 2008. However, the current consensus is that inflation may be peaking. If this is the case, then the Invesco Dynamic Leisure and Entertainment ETF (PEJ), US Global Jets ETF (JETS), Invesco QQQ Trust (QQQ), and the SPDR S&P Dividend ETF (SDY) are 4 ETFs worth buying. 

:  |  News, Ratings, and Charts

Is the Stock Market “Melting Up”?

The last few weeks the S&P 500 (SPY) has been beset with wild sector rotation. That is still at play. However, another trend may also be emerging that deserves some conversation. That is the notion of a market “melt up”. What is that? And what does it mean for our trading strategy? I will answer that and more in this week’s commentary. Read on below to find out more…

Read More Stories

More Mind Medicine (MindMed) Inc. (MNMD) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All MNMD News